Ivan Henriquez

Dr. Ivan Henriquez

Hospital Sant Joan
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1997 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
CCCarlos Conill
Carlos Conill
EVEugènia Verger
Eugènia Verger
IHIvan Henriquez
Ivan Henriquez
NSNeus Saiz
Neus Saiz
MEMontserrat Espier
Montserrat Espier
AGAndreu Garrigos
Andreu Garrigos

3 March 2013 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
Francesc GrausFrancesc Graus
Francesc Graus
JBJordi Bruna
Jordi Bruna
JPJavier Pardo
Javier Pardo
DEDomingo Escudero
Domingo Escudero
DVDolores Vilas
Dolores Vilas
EVEugènia Verger
Eugènia Verger
To assess management patterns and outcome in patients with glioblastoma multiforme (GBM) treated during 2008–2010 in Spain. Retrospective analysis of clinical, therapeutic, and survival data collected through filled questionnaires from patients with histologically confirmed GBM diagnosed in 19 Spanish hospitals. We identified 834 patients (23% aged >70 years). Surgical resection was achieved in 66% of patients, although the extent of surgery was confirmed by postoperative MRI in only 41%. There were major postoperative complications in 14% of patients, and age was the only independent predictor (Odds ratio [OR], 1.03; 95% confidence interval [CI],1.01–1.05; P = .006). After surgery, 57% received radiotherapy (RT) with concomitant and adjuvant temozolomide, 21% received other regimens, and 22% were not further treated. In patients treated with surgical resection, RT, and chemotherapy (n = 396), initiation of RT ≤42 days was associated with longer progression-free survival (hazard ratio [HR], 0.8; 95% CI, 0.64–0.99; P = .042) but not with overall survival (HR, 0.79; 95% CI, 0.62–1.00; P = .055). Only 32% of patients older than 70 years received RT with concomitant and adjuvant temozolomide. The median survival in this group was 10.8 months (95% CI, 6.8–14.9 months), compared with 17.0 months (95% CI, 15.5–18.4 months; P = .034) among younger patients with GBM treated with the same regimen. In a community setting, 57% of all patients with GBM and only 32% of older patients received RT with concomitant and adjuvant temozolomide. In patients with surgical resection who were eligible for chemoradiation, initiation of RT ≤42 days was associated with better progression-free survival.

17 September 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
IHIvan Henriquez
Ivan Henriquez
MRMack Roach
Mack Roach
TMTodd M Morgan
Todd M Morgan
ABAlberto Bossi
Alberto Bossi
JGJunior A. Gómez
Junior A. Gómez
FCFelipe Counago
Felipe Counago
Metastatic castration-resistant prostate cancer (mCRPC) encompasses a heterogeneous wide range of molecular tumor behavior and a high risk of progression. Early detection and treatment are therefore crucial in these patients. Treatment has improved drastically in recent years and many novel therapeutic agents are currently under investigation. However, due to the rapidly changing therapeutic landscape in mCRPC, it is difficult for clinicians to keep up to date with the latest innovations in this area. In the present narrative review, we discuss the current and emerging therapies for mCRPC as well as the clinical and molecular factors that can help predict which patients are most likely to benefit from these novel agents.

3 February 2016 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
Carmen BalanaCarmen Balana
Carmen Balana
RPRamon De Las Penas
Ramon De Las Penas
JSJuan Manuel Sepúlveda
Juan Manuel Sepúlveda
MGMiguel J. Gil-Gil
Miguel J. Gil-Gil
RLRaquel Luque
Raquel Luque
SFSalvador Villà Freixa
Salvador Villà Freixa

1 November 2010 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
BGBenjamín Guix
Benjamín Guix
JLJosé Antonio Lejárcegui
José Antonio Lejárcegui
JTJosé Ignacio Tello
José Ignacio Tello
GZGabriel Zanón
Gabriel Zanón
IHIvan Henriquez
Ivan Henriquez
IGInés Guix
Inés Guix

30 April 2014 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
IHIvan Henriquez
Ivan Henriquez
GSGemma Sancho
Gemma Sancho
AHAsunción Hervás-Morón
Asunción Hervás-Morón
BGBenjamin Guix
Benjamin Guix
JPJoan Pera
Joan Pera
APAlfredo Polo
Alfredo Polo
To evaluate efficacy and toxicity after salvage brachytherapy (BT) in prostate local recurrence after radiation therapy.